Karyopharm announces initiation of Selinexor Phase 2 study Karyopharm Therapeutics announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor, or KPT-330, in patients with metastatic hormone-refractory prostate cancer. The study, referred to as the SHIP, or Selinexor in Hormone Refractory Indications in Prostate Cancer, study, is led by Drs. Christopher Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.
News For KPTI From The Last 14 Days
Check below for free stories on KPTI the last two weeks.